IEIH ETF Report: Ratings, Analysis, Quotes, Holdings

Competing ETFs: SBIO

Find more ETFs with our ETF Screener and Database

*Unless otherwise stated, data provided by FactSet.

IEIH Fund Description

IEIH tracks an index that offers US pharmaceutical and biotechnology exposure as defined by the iETF Evolved Sector classification scheme.

IEIH Factset Analytics Insight

IEIH makes use of iShares’ “Evolved” sector classification scheme to provide exposure to a subset of the traditional US healthcare sector. Unlike traditional classification schemes, firms may be classified into more than one sector under the Evolved Sector system. Sector assignments are made using proprietary machine learning models. In this case, IEIH offers exposure to firms traditionally classified as pharmaceuticals and biotechnology. The combination means that the holdings and returns of IEIH may not match those of traditionally classified funds, so investors should use extra caution to be sure that holdings align with their investment objectives.

IEIH MSCI ESG Analytics Insight

iShares Evolved U.S. Innovative Healthcare ETF has an MSCI ESG Fund Rating of BB based on a score of 4.26 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. iShares Evolved U.S. Innovative Healthcare ETF ranks in the 24th percentile within its peer group and in the 39th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

IEIH Charts And Performance

Price Chart ($)

Total Return Chart (%)

1 Month
3 Months
YTD
1 Year
3 Years
5 Years
Max

1 Month
3 Months
YTD
1 Year
3 Years
5 Years
Max

Compare

Reset

Select ETFs to compare their performance:

PERFORMANCE [as of 09/18/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS

IEIH 0.90% -0.58% 6.55% -4.61% -- -- --

IEIH (NAV) 0.61% -2.02% 5.76% -5.80% -- -- --

No Underlying Index -- -- -- -- -- -- --

N/A -- -- -- -- -- -- --

All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

IEIH Summary Data

Blackrock

iShares

03/21/18

Open-Ended Fund

0.18%

$4.98M

$27.20K

0.21%

Fund Home Page

IEIH Portfolio Data

$105.65B

45.13

4.86

2.01%

09/24/19

222

IEIH Index Data

No Underlying Index

Fundamental

Market Cap

N/A

IEIH Portfolio Management

0.18%

IEIH Tax Exposures

20.00% / 39.60%

0.58%

Qualified dividends

IEIH Fund Structure

Open-Ended Fund

Yes

72% / 29%

N/A

High

Daily

Cboe Book Viewer

Top Of Book

Last 10 Trades

Bats BZX Real-time Quote -

IEIH Factset Analytics Block Liquidity

As of 09/19/19

This measurement shows how easy it is to trade a $1 million USD block of IEIH. IEIH is rated a 4 out of 5.

IEIH Tradability

1,102

$27.20K

769

$19.13K

0.21%

$0.05

0.01%

5.85% / -3.97%

None

100.00%

50,000

0.02

0.08%

0.01%

$24.85

IEIH Sector/Industry Breakdown

IEIH

Segment Benchmark

Pharmaceuticals

63.86%

Biotechnology & Medical Research

29.69%

Medical Equipment, Supplies & Distribution

4.75%

Advanced Medical Equipment & Technology

1.27%

Semiconductors

0.24%

Drug Retailers

0.15%

Communications & Networking

0.05%

IEIH Top 10 Holdings[View All]

Johnson & Johnson 10.45%

Merck & Co., Inc. 7.93%

Pfizer Inc. 6.47%

AbbVie, Inc. 4.91%

Celgene Corporation 4.66%

Amgen Inc. 4.66%

Bristol-Myers Squibb Company 4.63%

Eli Lilly and Company 4.63%

Gilead Sciences, Inc. 4.50%

Vertex Pharmaceuticals Incorporated 4.17%

76.71%

Mid (>2.7B)

15.68%

Small (>600M)

6.42%

Micro (<600M)

1.20%

The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional.

ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com.

[ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.

Data provider:
Terms of Use

MSCI ESG Research LLC’s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.